Andre F et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol 2022;40(16):1816-37. Abstract
Bardia A et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting. SABCS 2022;Abstract GS3-01.
Bartsch R et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: A single-arm, phase 2 trial. Nature Med 2022;28(9):1840-7. Abstract
Chan A et al. Effect of diarrheal prophylaxis or dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Final findings from the CONTROL trial. ESMO Breast 2022;Abstract P73.
Chan A et al. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial. Clin Breast Cancer 2021;21(1):80-91. Abstract
Cortes J et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 2022;387(3):217-26. Abstract
Curigliano G et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): Final overall survival analysis. Ann Oncol 2022;33(3):321-9. Abstract
Droste A, Schmid M. Endocrine therapy in metastatic breast cancer-more than just CDK4/6 inhibitors. J Cancer Metastasis Treat 2023;9:2. Abstract
Hurvitz SA et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 2023;401(10371):105-17. Abstract
Johnston SRD et al. Abemaciclib plus endocrine therapy for HER+, HER2-, node-positive, high-risk early breast cancer: Results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes. SABCS 2022;Abstract GS1-09.
Kalinsky KM et al. Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER). SABCS 2021;Abstract GS2-07.
Lambertini M et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient-level data. J Clin Oncol 2018;36(19):1981-90. Abstract
Lin NU et al. Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: Updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol 2023;9(2):197-205. Abstract
Modi S et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387(1):9-20. Abstract
Modi S et al. Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. ASCO 2022;Abstract LBA3.
Moore HCF et al. Final analysis of the prevention of early menopause study (POEMS)/SWOG intergroup S0230. J Natl Cancer Inst 2019;111(2):210-3. Abstract
Moy B et al. Chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor-negative metastatic breast cancer: ASCO guideline rapid recommendation update. J Clin Oncol 2023;41(6):1318-20. Abstract
Oliveira M et al. Camizestrant, a next-generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose phase 2 SERENA-2 trial. SABCS 2022;Abstract GS3-02.
Rugo HS et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: Safety and patient-reported outcomes from the monarchE study. Ann Oncol 2022;33(6):616-27. Abstract
Schmid P et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 2022;386(6):556-67. Abstract
Schmid P et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020;382(9):810-21. Abstract
Sparano JA et al. Trial assigning individualized options for treatment (TAILORx): An update including 12-year event rates. SABCS 2022;Abstract GS1-05.
Turner NC et al. Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III CAPItello-291 trial. SABCS 2022;Abstract GS3-04.
Tutt ANJ et al. Pre-specified event driven analysis of overall survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer. ESMO Virtual Plenary 2022;Abstract VP1-2022.